Table 3 Efficacy results
ITT population (N = 47) | |
|---|---|
Best objective response | |
Overall response rate, % | 6.4 |
Complete response, n (%) | 1 (2.1) |
Partial response, n (%) | 2 (4.3) |
Stable disease, n (%) | 21 (45) |
Progression disease, n (%) | 13 (28) |
Disease control rate, n % | 24 (51) |
Non-evaluable, n % | 10 (21) |
Progression free survival (months), median (95%CI) | 5.6 (2.7–8.4) |
Progression free survival, rate at 6 months (95%CI) | 45% (30–60) |
Overall survival (months), median (95%CI) | 16 (7.8–24) |
Time to treatment failure (months), median (95%CI) | 2.1 (1.3–2.9) |
Time to progression (months), median (95%CI) | 5.6 (1.9–9.3) |